Cholestasis Differentially Affects Liver Connexins.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Sep 2020
Historique:
received: 03 07 2020
revised: 26 08 2020
accepted: 05 09 2020
entrez: 10 9 2020
pubmed: 11 9 2020
medline: 23 2 2021
Statut: epublish

Résumé

Connexins are goal keepers of tissue homeostasis, including in the liver. As a result, they are frequently involved in disease. The current study was set up to investigate the effects of cholestatic disease on the production of connexin26, connexin32 and connexin43 in the liver. For this purpose, bile duct ligation, a well-known trigger of cholestatic liver injury, was applied to mice. In parallel, human hepatoma HepaRG cell cultures were exposed to cholestatic drugs and bile acids. Samples from both the in vivo and in vitro settings were subsequently subjected to assessment of mRNA and protein quantities as well as to in situ immunostaining. While the outcome of cholestasis on connexin26 and connexin43 varied among experimental settings, a more generalized repressing effect was seen for connexin32. This has also been observed in many other liver pathologies and could suggest a role for connexin32 as a robust biomarker of liver disease and toxicity.

Identifiants

pubmed: 32906817
pii: ijms21186534
doi: 10.3390/ijms21186534
pmc: PMC7116118
mid: EMS94842
pii:
doi:

Substances chimiques

Bile Acids and Salts 0
Connexin 43 0
Connexins 0
RNA, Messenger 0
Connexin 26 127120-53-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Research Council
ID : 861913
Pays : International
Organisme : University Hospital of the Vrije Universiteit Brussel-Belgium
ID : "Willy Gepts Fonds" UZ-VUB
Organisme : Fonds Wetenschappelijk Onderzoek
ID : G009514N, G010214N and G012318N
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : FAPESP SPEC grant 2013/50420-6 and FAPESP-FWO grant 18/10953-9

Références

J Gastroenterol. 2004 Aug;39(8):763-8
pubmed: 15338370
Hepatology. 1995 Jul;22(1):202-12
pubmed: 7601414
Toxicol Mech Methods. 2016 Jun;26(5):362-370
pubmed: 27268753
J Cell Biol. 1989 Mar;108(3):1039-51
pubmed: 2537831
Methods Mol Biol. 2015;1250:363-76
pubmed: 26272158
Toxicol In Vitro. 2003 Apr;17(2):191-9
pubmed: 12650673
Drug Metab Dispos. 2017 Dec;45(12):1292-1303
pubmed: 28928138
Cell Tissue Res. 1998 Nov;294(2):345-50
pubmed: 9799450
Clin Liver Dis (Hoboken). 2020 Apr 04;15(3):110-114
pubmed: 32257122
Biochim Biophys Acta. 2016 Jun;1862(6):1111-21
pubmed: 26912412
Verh Dtsch Ges Pathol. 1995;79:233-40
pubmed: 8600686
Cell Commun Adhes. 2012 Aug;19(3-4):55-62
pubmed: 22950570
J Hepatol. 2013 Jun;58(6):1194-200
pubmed: 23376361
Toxicol Appl Pharmacol. 2013 Dec 15;273(3):524-31
pubmed: 24096036
Arch Toxicol. 2018 Aug;92(8):2607-2627
pubmed: 29987408
Crit Rev Toxicol. 2019 Jul;49(6):520-548
pubmed: 31589080
Reprod Fertil Dev. 1995;7(3):603-11
pubmed: 8606973
Biochem Biophys Res Commun. 2009 Nov 20;389(3):431-6
pubmed: 19732748
Am J Physiol Gastrointest Liver Physiol. 2012 May 1;302(9):G925-36
pubmed: 22345550
Pflugers Arch. 2001 Sep;442(6):961-6
pubmed: 11680630
Int J Cancer. 2015 Jul 1;137(1):1-11
pubmed: 24752574
Arch Toxicol. 2020 Apr;94(4):1151-1172
pubmed: 32152650
J Appl Toxicol. 2018 Oct;38(10):1323-1335
pubmed: 29785833
Curr Med Chem. 2003 Oct;10(19):2045-58
pubmed: 12871102
Exp Cell Res. 1994 Jul;213(1):37-42
pubmed: 7517369
Hepatology. 1998 Dec;28(6):1616-20
pubmed: 9828226
J Biol Chem. 1995 Aug 4;270(31):18643-8
pubmed: 7629194
PLoS One. 2013 Aug 30;8(8):e72457
pubmed: 24023619
Cell Commun Adhes. 2001;8(4-6):299-302
pubmed: 12064606
Clin Exp Pharmacol Physiol. 2017 Feb;44(2):197-206
pubmed: 27859493
J Hepatol. 2009 Aug;51(2):237-67
pubmed: 19501929
Semin Cell Dev Biol. 2002 Dec;13(6):405-9
pubmed: 12468240
Microsc Res Tech. 2011 May;74(5):421-9
pubmed: 20830702
J Vis Exp. 2015 Feb 10;(96):
pubmed: 25741630
Cell Commun Adhes. 2015 Apr - Dec;22(2-6):29-37
pubmed: 27001459
Toxicol Pathol. 2000 Jul-Aug;28(4):540-7
pubmed: 10930040
Arch Toxicol. 2019 May;93(5):1169-1186
pubmed: 30972450
Biochem Biophys Res Commun. 2003 Jul 18;307(1):80-5
pubmed: 12849984
Hepatology. 2002 Sep;36(3):631-40
pubmed: 12198655
Methods Mol Biol. 2016;1437:1-19
pubmed: 27207283
Br J Surg. 2008 May;95(5):646-56
pubmed: 18196571
In Vivo. 2010 Jan-Feb;24(1):101-7
pubmed: 20133984
J Hepatol. 1996 Oct;25(4):529-37
pubmed: 8912153
Hepatology. 2019 Mar;69(3):1317-1323
pubmed: 30300925
Gastroenterol Res Pract. 2017;2017:2721547
pubmed: 28769978
Am J Pathol. 1998 Feb;152(2):347-52
pubmed: 9466559
J Hepatobiliary Pancreat Surg. 2001;8(3):259-67
pubmed: 11455489
Proc Natl Acad Sci U S A. 1983 Feb;80(3):755-9
pubmed: 6298773
Toxicol Sci. 2006 Jun;91(2):484-92
pubmed: 16531468
Hepatology. 2005 Aug;42(2):481-9
pubmed: 16025496
Exp Cell Res. 2004 Oct 1;299(2):427-41
pubmed: 15350541
Toxicol Appl Pharmacol. 2014 Jan 1;274(1):124-36
pubmed: 24211272
Arch Toxicol. 1999 Sep;73(7):373-80
pubmed: 10550479
Hepatology. 2011 Apr;53(4):1377-87
pubmed: 21480339
Carcinogenesis. 1996 Mar;17(3):537-44
pubmed: 8631141
Biomolecules. 2019 Oct 22;9(10):
pubmed: 31652629
J Cell Sci. 1995 Aug;108 ( Pt 8):2771-80
pubmed: 7593318
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Liver Int. 2014 Jul;34(6):859-68
pubmed: 24350605
Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151
pubmed: 11729749
Am J Physiol. 1992 Nov;263(5 Pt 1):G650-8
pubmed: 1332499
Gastroenterology. 2005 Feb;128(2):433-48
pubmed: 15685554
Annu Rev Biochem. 1996;65:475-502
pubmed: 8811187
Am J Physiol. 1995 May;268(5 Pt 1):C1186-94
pubmed: 7762611
Mech Dev. 2003 Jan;120(1):117-30
pubmed: 12490302
Cancer Res. 1994 Jun 15;54(12):3145-52
pubmed: 8205533
Shock. 2000 Jul;14(1):53-9
pubmed: 10909894
Methods Mol Biol. 2016;1437:55-70
pubmed: 27207286
Methods Mol Biol. 2016;1437:37-53
pubmed: 27207285
Liver. 2000 Apr;20(2):104-7
pubmed: 10847477
J Hepatol. 2019 Apr;70(4):759-772
pubmed: 30599172
Am J Physiol. 1999 May;276(5):R1249-57
pubmed: 10233014
Gastroenterology. 2004 Apr;126(4):1147-56
pubmed: 15057753
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 15;899:135-45
pubmed: 22664055
Anticancer Res. 1999 Nov-Dec;19(6A):4831-8
pubmed: 10697596
Sci Rep. 2016 May 12;6:24709
pubmed: 27169750
J Biol Chem. 1985 Mar 10;260(5):3097-107
pubmed: 3972818
J Cell Physiol. 1996 Feb;166(2):461-7
pubmed: 8592007

Auteurs

Axelle Cooreman (A)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Raf Van Campenhout (R)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Sara Crespo Yanguas (S)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Eva Gijbels (E)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Kaat Leroy (K)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Alanah Pieters (A)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Andrés Tabernilla (A)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Pieter Van Brantegem (P)

Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, 3000 Leuven, Belgium.

Pieter Annaert (P)

Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, 3000 Leuven, Belgium.

Bruno Cogliati (B)

Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05508-270, Brazil.

Mathieu Vinken (M)

Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH